Efficacy and Safety of Eslicarbazepine Acetate as First Add-on to Levetiracetam or Lamotrigine Monotherapy or as Later Adjunctive Treatment for Subjects With Uncontrolled Partial-onset Seizures: A Multicenter, Open-label, Non-randomized Trial
Latest Information Update: 14 Aug 2023
At a glance
- Drugs Eslicarbazepine acetate (Primary) ; Lamotrigine; Levetiracetam
- Indications Partial epilepsies; Seizures
- Focus Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 01 Feb 2023 Results of post hoc analysis assessing time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial published in the Clinical Neurology and Neurosurgery
- 06 Dec 2022 Results of post-hoc analysis assessing the effect of response to eslicarbazepine acetate treatment as first adjunctive therapy on Health-related Quality of Life, presented at the 76th Annual Meeting of the American Epilepsy Society.
- 22 Apr 2021 Results of post-hoc analysis assessing the efficacy outcomes presented at the 73rd Annual Meeting of the American Academy of Neurology